Literature DB >> 17702098

Diabetic nephropathy in the elderly.

J F Blicklé1, J Doucet, T Krummel, T Hannedouche.   

Abstract

Renal impairment is frequent in aged diabetic patients, notably with type 2 diabetes. It results from a multifactorial pathogeny, particularly the combined actions of hyperglycaemia, arterial hypertension and ageing. Diabetic nephropathy (DN) is associated with an increased cardiovascular mortality. DN often leads to end stage renal failure (ESRF) which causes specific problems of decision and practical organization of extra-renal epuration in diabetic and aged patients. In the absence of renal biopsy, clinical signs are often insufficient to assess the diabetic origin of a nephropathy in an elderly diabetic patient. Prevention of DN is principally based on tight glycaemic and blood pressure control. The progression of renal lesions can be retarded by strict blood pressure control, notably by blocking of the renin-angiotensin system, if well tolerated in aged patients. It is absolutely necessary to avoid the worsening of renal lesions by potentially nephrotoxic products, notably non steroidal anti-inflammatory drugs (NSAIDs) and iodinated contrast media. At the stage of renal failure, it is important to adapt the antidiabetic treatment, and in the majority of the cases, to switch to insulin when glomerular filtration rate (GFR) is below 30 ml/mn/1.73 m2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17702098     DOI: 10.1016/s1262-3636(07)80056-5

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  7 in total

1.  Protective effects of low-dose rapamycin combined with valsartan on podocytes of diabetic rats.

Authors:  Jin Zhang; Xiaozhou Hu; Shaoting Wang; Yan Zhang; Hong Yang
Journal:  Int J Clin Exp Med       Date:  2015-08-15

2.  Renoprotective effect of lansoprazole in streptozotocin-induced diabetic nephropathy in wistar rats.

Authors:  Rupinder Kaur; Rupinder Kaur Sodhi; Neha Aggarwal; Jaspreet Kaur; Upendra K Jain
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-10-16       Impact factor: 3.000

3.  Community pharmacist intervention in patients with renal impairment.

Authors:  Xavier Pourrat; Anne-Sophie Sipert; Philippe Gatault; Bénédicte Sautenet; Nicolas Hay; Francis Guinard; Françoise Guegan; Jean-Michel Halimi
Journal:  Int J Clin Pharm       Date:  2015-09-18

Review 4.  Key priorities in managing glucose control in older people with diabetes.

Authors:  I Bourdel Marchasson; J Doucet; B Bauduceau; G Berrut; J F Blickle; P Brocker; T Constans; A Fagot Campagna; E Kaloustian; V Lassmann Vague; P Lecomte; D Simon; D Tessier; C Verny; U M Vischer
Journal:  J Nutr Health Aging       Date:  2009-10       Impact factor: 4.075

5.  Effects of Selected Anionic β-Cyclodextrins on Persistence of Blood Glucose Lowering by Insulin Glargine after Subcutaneous Injection to Rats.

Authors:  Keiko Uehata; Takayuki Anno; Kayoko Hayashida; Keiichi Motoyama; Taishi Higashi; Fumitoshi Hirayama; Naomi Ono; James D Pipkin; Kaneto Uekama; Hidetoshi Arima
Journal:  J Drug Deliv       Date:  2011-12-11

6.  Experience with vildagliptin in patients ≥75 years with type 2 diabetes and moderate or severe renal impairment.

Authors:  Anja Schweizer; Sylvie Dejager
Journal:  Diabetes Ther       Date:  2013-07-03       Impact factor: 2.945

7.  [Approach to podiatric status of the diabetic patient in chronic hemodialysis in a Moroccan hospital].

Authors:  Nawal Benabdellah; Ilham Karimi; Yassamine Bentata; Intissar Haddiya
Journal:  Pan Afr Med J       Date:  2013-09-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.